Clopidogrel

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1997

www.ebi.ac.uk

First approval year: 1997
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Clopidogrel
www.ebi.ac.uk

Molecular weight: 321.83
www.ebi.ac.uk

Structure (SMILES): COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
www.ebi.ac.uk

(+)-(S)-CLOPIDOGREL
(S)-METHYL .ALPHA.-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRIDIN-5-YL)-.ALPHA.-(O-CHLOROPHENYL)ACETATE
clopidogrel
Clopidogrel
CLOPIDOGREL [EMA EPAR]
CLOPIDOGREL [HSDB]
clopidogrel [INN]
CLOPIDOGREL [MI]
CLOPIDOGREL [VANDF]
Clopidogrel [WHO-DD]
clopidogrel ema epar
clopidogrel hsdb
clopidogrel inn
clopidogrel mi
clopidogrel vandf
clopidogrel who dd
nsc 758613
NSC-758613
r 130964
R 130964
R-130964
s clopidogrel
s methyl alpha 4 5 6 7 tetrahydrothieno 3 2 c pyridin 5 yl alpha o chlorophenyl acetate
sr 25990
SR 25990

And 5 more, listed on the interactive page.

CAS registry numbers

113665-84-2

ChEMBL ID: CHEMBL1771
www.ebi.ac.uk

InChIKey: GKTWGGQPFAXNFI-HNNXBMFYSA-N
www.ebi.ac.uk

PubChem compound IDs

60606

FDA ingredient codes (UNII)

A74586SNO7

B01AC03
B01AC04
B01AC06

Sources for recorded values

www.ebi.ac.uk

32968
236991

Applicant: SANOFI AVENTIS US
Approval date: 17 Nov 1997
Application number: NDA020839

Status: Authorised
Status date: 14 Jul 1998
Authorisation date: 14 Jul 1998
Approved indications: Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Adult patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in: Adult patients with moderate to high-risk TIA (ABCD2 score ?4) or minor IS (NIHSS ?3) within 24 hours of either the TIA or IS event. Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Product number: EMEA/H/C/000175
Authorisation holder: Sanofi Winthrop Industrie
Priority medicines scheme: No
Generic: No
Biosimilar: No
Generic medicines: 11
Biosimilar medicines: 0
Advanced therapy: No
Conditional approval: No
Additional monitoring: No
Accelerated assessment: No
Exceptional circumstances: No

Therapeutic areas

Acute Coronary Syndrome
Atrial Fibrillation
Myocardial Infarction
Peripheral Vascular Diseases
Stroke

European medicines record

www.ema.europa.eu

First in class: No
Orphan designation: No
Availability: Prescription only
Boxed warning: Yes

United States (FDA): Approved
European Union (EMA): Authorised

Pharmacology name: clopidogrel
Type: Synthetic organic
Drug name stem: -grel
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral

Open Targets mechanisms

Mechanism
Purinergic receptor P2Y12 antagonist
Action type
Antagonist
Target
P2Y purinoceptor 12

DrugCentral mechanisms

Action type
Antagonist
Gene symbol
P2RY12
Protein identifier
Q9H244
Organism
Homo sapiens
Target development level
Clinical

Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000180
Subject identifier
D015658
Condition
Aortic Valve Stenosis
Highest recorded phase
3
Condition identifier
EFO:0000266
Subject identifier
D001024
Condition
Atrial Fibrillation
Highest recorded phase
3
Condition identifier
EFO:0000275
Subject identifier
D001281
Condition
Cardiovascular Diseases
Highest recorded phase
2
Condition identifier
EFO:0000319
Subject identifier
D002318
Condition
Pulmonary Disease, Chronic Obstructive
Highest recorded phase
3
Condition identifier
EFO:0000341
Subject identifier
D029424
Condition
Ischemia
Highest recorded phase
3
Condition identifier
EFO:0000556
Subject identifier
D007511
Condition
Myocardial Infarction
Highest recorded phase
3
Condition identifier
EFO:0000612
Subject identifier
D009203
Condition
Stroke
Highest recorded phase
3
Condition identifier
EFO:0000712
Subject identifier
D020521
Condition
Scleroderma, Systemic
Highest recorded phase
2
Condition identifier
EFO:0000717
Subject identifier
D012595
Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Hypertension, Pulmonary
Highest recorded phase
2
Condition identifier
EFO:0001361
Subject identifier
D006976
Condition
Macular Degeneration
Highest recorded phase
3
Condition identifier
EFO:0001365
Subject identifier
D008268
Condition
Coronary Disease
Highest recorded phase
3
Condition identifier
EFO:0001645
Subject identifier
D003327
Condition
Polycythemia Vera
Highest recorded phase
2
Condition identifier
EFO:0002429
Subject identifier
D011087
Condition
Carotid Stenosis
Highest recorded phase
3
Condition identifier
EFO:0002615
Subject identifier
D016893
Condition
Pancreatic Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0002618
Subject identifier
D010190
Condition
Pregnancy
Highest recorded phase
2
Condition identifier
EFO:0002950
Subject identifier
D011247
Condition
Pneumonia
Highest recorded phase
3
Condition identifier
EFO:0003106
Subject identifier
D011014
Condition
Heart Failure
Highest recorded phase
3
Condition identifier
EFO:0003144
Subject identifier
D006333
Condition
Ischemic Attack, Transient
Highest recorded phase
3
Condition identifier
EFO:0003764
Subject identifier
D002546
Condition
Heart Diseases
Highest recorded phase
2
Condition identifier
EFO:0003777
Subject identifier
D006331
Condition
Intracranial Aneurysm
Highest recorded phase
3
Condition identifier
EFO:0003870
Subject identifier
D002532
Condition
Peripheral Vascular Diseases
Highest recorded phase
2
Condition identifier
EFO:0003875
Subject identifier
D016491
Condition
Intermittent Claudication
Highest recorded phase
2
Condition identifier
EFO:0003876
Subject identifier
D007383
Condition
Renal Insufficiency, Chronic
Highest recorded phase
3
Condition identifier
EFO:0003884
Subject identifier
D051436

And 30 more, listed on the interactive page.

Condition identifier
EFO_0000266
Highest recorded phase
3
Condition identifier
EFO_0000275
Condition identifier
EFO_0000319
Highest recorded phase
1
Condition identifier
EFO_0000341
Highest recorded phase
3
Condition identifier
EFO_0000400
Highest recorded phase
3
Condition identifier
EFO_0000556
Highest recorded phase
3
Condition identifier
EFO_0000612
Condition identifier
EFO_0000712
Condition identifier
EFO_0001365
Highest recorded phase
3
Condition identifier
EFO_0001425
Condition identifier
EFO_0001645
Highest recorded phase
3
Condition identifier
EFO_0002756
Highest recorded phase
1
Condition identifier
EFO_0002950
Condition identifier
EFO_0002950
Highest recorded phase
2
Condition identifier
EFO_0003764
Highest recorded phase
3
Condition identifier
EFO_0003776
Condition identifier
EFO_0003781
Condition identifier
EFO_0003870
Highest recorded phase
3
Condition identifier
EFO_0003875
Condition identifier
EFO_0003876
Highest recorded phase
2
Condition identifier
EFO_0003884
Highest recorded phase
3
Condition identifier
EFO_0003906
Condition identifier
EFO_0003913
Highest recorded phase
3
Condition identifier
EFO_0003914
Highest recorded phase
3
Condition identifier
EFO_0003964

And 85 more, listed on the interactive page.

Warnings

Warning
Black Box Warning

Open Targets warnings

Warning
Black Box Warning
Country
United States

Event
acute myocardial infarction
Reports
416
Reporting signal score
447.777
Event
anaemia
Reports
2,316
Reporting signal score
2,168.93
Event
cerebral haemorrhage
Reports
518
Reporting signal score
806.703
Event
drug interaction
Reports
1,390
Reporting signal score
825.138
Event
epistaxis
Reports
698
Reporting signal score
647.136
Event
gastric haemorrhage
Reports
318
Reporting signal score
540.365
Event
gastrointestinal haemorrhage
Reports
2,032
Reporting signal score
3,345.65
Event
haematemesis
Reports
657
Reporting signal score
1,101.78
Event
haematochezia
Reports
862
Reporting signal score
1,299.26
Event
haematoma
Reports
599
Reporting signal score
869.992
Event
haematuria
Reports
592
Reporting signal score
690.93
Event
haemoglobin decreased
Reports
907
Reporting signal score
602.991
Event
haemoptysis
Reports
384
Reporting signal score
469.326
Event
haemorrhage
Reports
836
Reporting signal score
770.967
Event
labelled drug-drug interaction medication error
Reports
394
Reporting signal score
806.66
Event
lower gastrointestinal haemorrhage
Reports
226
Reporting signal score
408.394
Event
melaena
Reports
1,026
Reporting signal score
2,062.46
Event
multiple injuries
Reports
114
Reporting signal score
341.58
Event
rectal haemorrhage
Reports
765
Reporting signal score
1,130.45
Event
shock haemorrhagic
Reports
193
Reporting signal score
370.87
Event
subdural haematoma
Reports
410
Reporting signal score
734.862
Event
upper gastrointestinal haemorrhage
Reports
535
Reporting signal score
1,031.68
Event
vascular pseudoaneurysm
Reports
139
Reporting signal score
344.175
Event
vascular stent thrombosis
Reports
277
Reporting signal score
811.039

NCT00007683
clinicaltrials.gov
NCT00050817
clinicaltrials.gov
NCT00059215
clinicaltrials.gov
NCT00935506
clinicaltrials.gov
NCT03392051
clinicaltrials.gov
NCT00059306
clinicaltrials.gov
NCT00238667
clinicaltrials.gov
NCT01661322
clinicaltrials.gov
NCT03961334
clinicaltrials.gov
NCT04420351
clinicaltrials.gov
NCT04824911
clinicaltrials.gov
NCT00097591
clinicaltrials.gov
NCT00335452
clinicaltrials.gov
NCT00356135
clinicaltrials.gov
NCT00385944
clinicaltrials.gov
NCT00391872
clinicaltrials.gov
NCT00699998
clinicaltrials.gov
NCT00714961
clinicaltrials.gov
NCT00830960
clinicaltrials.gov
NCT01107899
clinicaltrials.gov
NCT01109784
clinicaltrials.gov
NCT01115738
clinicaltrials.gov
NCT01294462
clinicaltrials.gov
NCT01422109
clinicaltrials.gov
NCT01465828
clinicaltrials.gov

And 135 more, listed on the interactive page.

Dose: 300mg for loading dose, then 75mg
Route: Oral
How often: Once daily

Hydrogen bond acceptors: 4
Hydrogen bond donors: 0
Polar surface area: 29.54
Calculated partition coefficient (ALogP): 3.67
Calculated partition coefficient (XLogP): 3.8
Prodrug: Yes
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 3
Heavy atoms: 21
Molecular formula: C16H16ClNO2S
Monoisotopic mass: 321.0590276
Natural product: Yes

31722-758
31722-759

Recorded assays: 1,921
Active assays: 28

Confirmatory
Other

Platelet Aggregation Inhibitors
id.nlm.nih.gov
Purinergic P2Y Receptor Antagonists
id.nlm.nih.gov

These details could not be displayed.

Related records

Trials (649)

1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient
A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
A Clinical Trial of Antiplatelets in Psoriasis
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
A Pharmacodynamic Study With Ticagrelor in African American Patients
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

Approved for (1)

Thrombotic disease

In development for (64)

Acquired polycythemia vera Phase 2
Acute coronary syndrome Phase 3
Acute myocardial infarction Phase 3
Age-related macular degeneration Phase 3
Alzheimer disease Phase 2
Aortic valve stenosis Phase 3
Arteriosclerosis disorder Phase 3
Asthma Phase 2
Atherosclerosis Phase 3
Atrial fibrillation Phase 3
Brain aneurysm Phase 3
Brain infarction Phase 3
Breast cancer Phase 2
Cardiovascular disorder Phase 2
Cerebral atherosclerosis Phase 3
Cerebral infarction Phase 3
Cervical artery dissection Phase 3
Chronic kidney disease Phase 3
Chronic obstructive pulmonary disease Phase 3
Chronic renal failure syndrome Phase 3

Targets (1)

P2RY12 Purinergic receptor P2Y12 antagonist

Clopidogrel

Development status

Names and chemistry

Other names (30)

Identifiers

ATC classification codes (3)

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

European Union

Therapeutic areas

Other regulatory facts

Approval status

Pharmacology

Drug classification

Administration routes

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (55)

Open Targets indications (110)

Warnings

Open Targets warnings

Reported adverse events (24)

Trial references (160)

Dosing

Chemical properties

National Drug Codes

Evidence counts

Active assay types (2)

Pharmacologic actions

Biological measurements

Related records

Trials (649)

Approved for (1)

In development for (64)

Other linked conditions (7)

Targets (1)